As detailed, inhibition of IL-6 by tocilizumab may dampen excessive inflammation in initial states of severe disease, avoiding subsequent oedema and fibrosis progression [26, 76, 77], which is reflected in our AI-based analysis through normalization of the inflammatory cytokine storm and pulmonary fibrosis, displaying a high intensity and a moderate coverage. The gene discussed is IL6; the disease is pulmonary fibrosis.